Provided by Tiger Trade Technology Pte. Ltd.

Corgi Genomics & Precision Medicine ETF

37.52
+1.413.90%
Post-market: 37.520.00000.00%16:10 EDT
Volume:526
Turnover:19.69K
Market Cap:1.31M
PE:- -
High:37.59
Open:37.25
Low:37.25
Close:36.11
52wk High:39.65
52wk Low:23.88
Shares:35.00K
Float Shares:35.00K
Volume Ratio:0.09
T/O Rate:1.50%
Dividend:- -
Dividend Rate:- -
ROE:--
ROA:--
PB:--
PE(LYR):- -

Loading ...

Maze jumps 25% to $27.99 after Vertex kidney disease data

TIPRANKS
·
Sep 22

Vertex Pharmaceuticals Incorporated Says Inaxaplin Reduces UACR by -42.7% at Week 13 in AMKD with Modest Proteinuria

Reuters
·
Sep 22

Vertex Pharmaceuticals Reports Positive Results for Inaxaplin Kidney Disease Trial

MT Newswires Live
·
Sep 22

Vertex Pharmaceuticals announces positive results from Phase 2b inaxaplin study

TIPRANKS
·
Sep 22

Vertex Says Phase 2b Amplified Study Shows Inaxaplin Cuts Proteinuria in APOL1-Mediated Kidney Disease Patients with Modest Proteinuria

Reuters
·
Sep 22

Vertex Pharmaceuticals Incorporated - Inaxaplin Reduces Uacr by -42.7% at Week 13 in Amkd with Modest Proteinuria

THOMSON REUTERS
·
Sep 22

Vertex Pharmaceuticals Incorporated - Inaxaplin Generally Safe and Well Tolerated in Both Amkd Cohorts

THOMSON REUTERS
·
Sep 22

Vertex Announces Positive Results from Phase 2B Amplified Study of Inaxaplin in Additional Populations of People with Apol1-Mediated Kidney Disease (Amkd) and Completion of Enrollment in the Phase 2/3 Amplitude Trial

THOMSON REUTERS
·
Sep 22

Insight Molecular Diagnostics Revises Chronix Royalty Agreement Terms

TIPRANKS
·
Sep 22

Agilent Technologies Inc. Stock Outperforms Competitors on Strong Trading Day

Dow Jones
·
Sep 22

InspireMD Announces Amendments to Certain Series J and Series K Warrants, Providing Potential Gross Proceeds of Up to $11 Million

GlobeNewswire
·
Sep 21

Analysts Offer Insights on Healthcare Companies: Innate Pharma (IPHA) and Alnylam Pharma (ALNY)

TIPRANKS
·
Sep 21

Vertex Pharmaceuticals Incorporated : Leerink Partners Resumes Coverage with Outperform Rating; Target Price $594

THOMSON REUTERS
·
Sep 21

Ultragenyx price target raised to $35 from $32 at Barclays

TIPRANKS
·
Sep 21

Correction to Vertex Material Listing Article on Sept. 17

Dow Jones
·
Sep 21

Steris PLC Stock Underperforms Friday When Compared to Competitors

Dow Jones
·
Sep 19

Amneal Pharmaceuticals announces FDA approval and launch of Lanreotide

TIPRANKS
·
Sep 19

Electra Therapeutics indicated to open at $20, IPO priced at $15

TIPRANKS
·
Sep 18

Abeona Therapeutics ‘congratulated’ Ultragenyx on U.S FDA approval of UX111

TIPRANKS
·
Sep 18

Vertex wins approval for 24/7 underground operations at Reward Gold Mine

TIPRANKS
·
Sep 18